With the capital increase, the number of issued shares will increase from 6,234,423 to 6,639,618 shares, corresponding to an increase of subscribed share capital in common stock from EUR 18,703,269 to EUR 19,918,845.
'Today's successful funding allows us the flexibility to further expand the research antibody side of our business. The unit has witnessed significant organic growth, not to mention two acquisitions since 2005,' commented Dave Lemus, Chief Financial Officer at MorphoSys AG.